S&P 500

5.667,20

0,64%

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

AZN

AstraZeneca (AZN)

AstraZeneca PLC

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AZN

<< Previous 34 35 36 37 38 39 40 41 42 43 44 45 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
10/02/2009	14h37	PR Newswire (US)	AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008	NYSE:AZN
09/02/2009	11h00	PR Newswire (US)	AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration	NYSE:AZN
19/12/2008	14h00	PR Newswire (US)	AstraZeneca Submits sNDA for NEXIUM(R) for the Short-Term Treatment of GERD in Infants 0 to 1 Year Old	NYSE:AZN
25/11/2008	21h09	PR Newswire (US)	AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva	NYSE:AZN
29/10/2008	18h00	PR Newswire (US)	Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD	NYSE:AZN
24/09/2008	00h57	PR Newswire (US)	US Court Denies Teva's Motion for Summary Judgment in PULMICORT RESPULES(R) Patent Litigation	NYSE:AZN
22/09/2008	19h23	PR Newswire (US)	AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA	NYSE:AZN
10/09/2008	14h00	PR Newswire (US)	National Survey Reveals Contradictory Awareness Levels of High Cholesterol and Atherosclerosis Among Hispanic Americans	NYSE:AZN
10/09/2008	14h00	PR Newswire (US)	Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma	NYSE:AZN
20/05/2008	14h15	PR Newswire (US)	New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in	NYSE:AZN
21/02/2008	21h59	PR Newswire (US)	AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Co	NYSE:AZN
05/11/2007	14h00	PR Newswire (US)	New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure	NYSE:AZN
16/10/2007	14h25	PR Newswire (US)	Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms	NYSE:AZN
25/09/2007	16h08	PR Newswire (US)	Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients	NYSE:AZN
18/09/2007	15h54	PR Newswire (US)	AstraZeneca Launches New Virtual Fund-Raising Activity to Honor Breast Cancer Survivors	NYSE:AZN
10/09/2007	15h42	PR Newswire (US)	Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health'	NYSE:AZN
07/08/2007	16h00	PR Newswire (US)	Breast Cancer Survivors Carry Optimistic Outlook on Life, Yet Lack Critical Information about Reducing Recurrence	NYSE:AZN
24/05/2007	17h00	PR Newswire (US)	American Cancer Society to Break Ground for AstraZeneca Hope Lodge in Philadelphia	NYSE:AZN
22/05/2007	15h01	PR Newswire (US)	New Research Examines Relationship Between GERD and Other Health Conditions	NYSE:AZN
12/05/2007	00h14	PR Newswire (US)	Latinas Make a Special Commitment to Healthy Hearts this Mother's Day	NYSE:AZN
09/05/2007	20h11	PR Newswire (US)	AstraZeneca U.S. Honored By The National Business Group on Health As One of Best Employers for Healthy Lifestyles	NYSE:AZN
26/02/2007	15h01	PR Newswire (US)	AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer	NYSE:AZN
09/11/2006	15h00	PR Newswire (US)	Childhood Acid Reflux Disease Poses Challenges for Many Families, National Survey Reveals	NYSE:AZN
02/11/2006	12h00	PR Newswire (US)	AstraZeneca Helps More People Afford Its Medicines	NYSE:AZN
18/05/2006	15h03	PR Newswire (US)	World's Most Comprehensive Survey of Stroke Experience Launched at European Stroke Conference	NYSE:AZN
24/03/2006	14h00	PR Newswire (US)	First-Ever Large-Scale Prospective Study in Hispanic Patients With Elevated Cholesterol Demonstrates Significant Cholesterol Re	NYSE:AZN
14/03/2006	09h30	PR Newswire (US)	Headline Results From CHANT Safety and Tolerability Study In Intracerebral Hemorrhage (ICH) Show NXY-059 Achieved Key Endpoints	NYSE:AZN
08/02/2006	23h01	PR Newswire (US)	New England Journal of Medicine Publishes NXY-059 Study, the First International Study of a Neuroprotectant to Show Reduced Disa	NYSE:AZN
22/10/2005	20h00	PR Newswire (US)	Head to Head Study Confirms Atypical Antipsychotic Efficacy Equivalence	NYSE:AZN
21/10/2005	09h59	PR Newswire (US)	BOLDER II Study Confirms Therapeutic Potential of SEROQUEL in Bipolar Depression	NYSE:AZN